RESEARCH TRIANGLE PARK – Agtech startup Vestaron has closed on an $82 million round of capital in a Series C round, the company disclosed Monday.

The company recently won approval to sell its biopesticide in Mexico and is seeking FDA approval for a second line of products.

Vestaron develops biopesticides that target the nicotinic acetylcholine receptor of the insect’s nervous system.

Investors include Ordway Selections and Cavallo Ventures plus Argonautic Ventures, Fortistar, and Endeavor8.

“Farmers, consumers, and governments deserve an alternative to chemical pesticides and their terrible side effects. The efficacy of Vestaron’s products, the company’s scalable manufacturing processes, and the involvement of some of the leading strategic and financial investors allows Ordway Selections to confidently state that Vestaron is at an inflection point. We are delighted to be partnering with Anna Rath and her talented team to globalize an impactful range of biological products that is simple for farmers to apply and benefit of,” said Ariel Barack, head of Food & Agriculture, Partner, Ordway Selections, in the announcement.

Previous investors include Novo Holdings, Northpond Ventures, CGC Ventures, iSelect and Syngenta Ventures.

As part of the deal, new board members include Ariel Barack (Ordway), Mike Wilbur (Cavallo), and Craig Herron (iSelect) as board observers.

“With the caliber of additional investors, our recently added Board of Directors, Randy Papadellis, and Audit Chair Susan Altschuller, Vestaron is primed for a strong and dynamic future,” noted Vestaron CEO, Anna Rath.